/apple-app-store.png?width=97&name=apple-app-store.png)
/google-play.png?width=88&name=google-play.png)
March 20, 2023 at 7:13 PM
An updated Executive Informational Overview (EIO) is now available on CEL-SCI Corporation, a clinical-stage biotechnology company developing immunotherapy technologies to treat cancer, autoimmune, and infectious diseases. The 98-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.
Topics: biotech, immunotherapy, CEL-SCI, infectious diseases, leaps, cancer, autoimmune, head and neck cancer, squamous cell carcinoma, rheumatoid arthritis, covid19, cervical dysplasia
June 3, 2020 at 12:34 PM
An Executive Informational Overview (EIO) is now available on CEL-SCI Corporation, a clinical-stage biotechnology company developing immunotherapy technologies to treat cancer, autoimmune, and infectious diseases. The 86-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.
Topics: biotech, immunotherapy, CEL-SCI, infectious diseases, leaps, cancer, autoimmune, head and neck cancer, squamous cell carcinoma, rheumatoid arthritis, covid19, cervical dysplasia
/facebook.png)
FACEBOOK/twitter.png)
TWITTER/youtube.png)
YOUTUBE/linkedin.png)
LINKEDIN/slideshare.png)
SLIDESHARE/rss.png)
RSS